IDH2 and glioblastoma: According to the results of this genetic analysis, patients were classified as type II (“IDH mutant astrocytoma”, 16% of patients), type I (“1p/19q codeletion oligodendroglioma”, 19% of patients), type III (“7+/10q− or TERT mut and 1p/19q intact glioblastoma”, 46% of patients), “childhood glioblastoma” (H3F3A mut, 2% of patients), and unclassified patients (7% of patients) [149] (Figure 5).